Evidence map›Paper›PMID 38034128›Full record

ArticleTobacco induced diseases2023

Smoking history and breast cancer risk by pathological subtype: MCC-Spain study.

Belén Peñalver-Argüeso, Esther García-Esquinas, Adela Castelló, Nerea Fernández de Larrea-Baz, Gemma Castaño-Vinyals, Pilar Amiano, Tania Fernández-Villa, Marcela Guevara, Guillermo Fernández-Tardón, Juan Alguacil and 13 more

Open access · goldAbstract read
In one paragraph

Article in Tobacco induced diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 2 countries.

Belén Peñalver-ArgüesoPublic Health and Preventive Medicine Teaching Unit, National School of Public Health, Carlos III Institute of Health, Madrid, Spain.
Esther García-EsquinasDepartment of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Adela CastellóDepartment of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Nerea Fernández de Larrea-BazDepartment of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Gemma Castaño-VinyalsConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Pilar AmianoConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Tania Fernández-VillaConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Marcela GuevaraConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Guillermo Fernández-TardónConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Juan AlguacilConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Mireia Obón-SantacanaConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Inés Gómez-AceboConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Marina Pinto-CarbóCancer and Public Health Research Area, Foundation for the Promotion of Health and Biomedical Research, Valencia, Spain.
Rafael Marcos-GrageraConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Nuria AragonésConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Amaia AizpuruaConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Vicente Martín-SánchezConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Eva ArdanazConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Trinidad Dierssen-SotosConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Jose Juan Jiménez-MoleónConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Manolis KogevinasConsortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain.
Marina PollánDepartment of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Beatriz Pérez-GómezPublic Health and Preventive Medicine Teaching Unit, National School of Public Health, Carlos III Institute of Health, Madrid, Spain.
Instituto de Salud Carlos III · ESBasque Government · ESCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESInstituto de Salud Pública de Navarra · ESUniversidad de Cantabria · ESUniversidad de Oviedo · ESUniversitat Pompeu Fabra · ESBellvitge University Hospital · ESFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESGeneralitat de Catalunya · ESNational Institute of Epidemiology · INUniversidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe role of cigarette smoking on breast cancer risk remains controversial, due to its dual carcinogenic-antiestrogenic action.

methodsIn the population-based multi-case-control study (MCC-Spain), we collected epidemiological and clinical information for 1733 breast cancer cases and 1903 controls, including smoking exposure. The association with breast cancer, overall, by pathological subtype and menopausal status, was assessed using logistic and multinomial regression models.

resultsSmokers had higher risk of premenopausal breast cancer, particularly if they had smoked ≥30 years (AOR=1.75; 95% CI: 1.04-2.94), although most estimates did not achieve statistical significance. In contrast, among postmenopausal women, smoking was associated with lower risk of breast cancer, mainly in overweight and obese women. The strongest risk reductions were observed among postmenopausal women who had stopped smoking ≥10 years before cancer diagnosis, particularly for HER2+ tumors (AOR=0.28; 95% CI: 0.11-0.68); p for heterogeneity = 0.040). Also, those who had smoked <10 pack-years (AOR=0.68; 95% CI: 0.47-0.98) or 10-25 pack-years (AOR=0.62; 95% CI: 0.42-0.92) during their lifetime were at a reduced risk of all breast cancer subtypes (p for heterogeneity: 0.405 and 0.475, respectively); however, women who had smoked more than 25 pack-years showed no reduced risk.

conclusionsMenopausal status plays a key role in the relationship between tobacco and breast cancer for all cancer subtypes. While smoking seems to increase the risk in premenopausal woman, it might be associated to lower risk of breast cancer among postmenopausal women with excess weight.

Indexed as

breast cancerHER2hormone receptorobesitysmoking

Identifiers

PMID38034128
PMCPMC10688255
OpenAlexW4389206867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.